152020-30-9

Basic information

• Product Name: L-Valine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-, 2-cyclohexyl 3-(phenylmethyl) ester
• CAS NO: 152020-30-9
• Molecular Formula: C29H43N3O8
• Molecular Weight: 561.676
• Mol File: 152020-30-9.mol

Chemical Properties

• CAS DataBase Reference: L-Valine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-, 2-cyclohexyl 3-(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Valine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-, 2-cyclohexyl 3-(phenylmethyl) ester(152020-30-9)
• EPA Substance Registry System: L-Valine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-a-aspartyl-, 2-cyclohexyl 3-(phenylmethyl) ester(152020-30-9)

Safety Data

• Hazardous Substances Data: 152020-30-9(Hazardous Substances Data)

Upstream product

• 4530-20-5 BOC-glycine 
• 152020-29-6 H-Asp(OcHx)-Val-OBzl 
• 152020-28-5 Boc-Asp(OcHex)-Val-OBzl 
• 66447-55-0 ((S)-1-benzylcarbamoyl-2-methyl-propyl)-carbamic acid tert-butyl ester 
• 73821-95-1 Boc-Asp(O-cyclohexyl)-OH 
• 67084-40-6 1-(N-tert-butoxycarbonyl-glycyloxy)-1H-benzotriazole 

Downstream Products

• 152020-31-0 (S)-2-[(S)-2-(2-Amino-acetylamino)-3-cyclohexyloxycarbonyl-propionylamino]-3-methyl-butyric acid benzyl ester 
• 910117-28-1 C₆₂H₇₉N₉O₁₅S 
• 93674-99-8 RGDV 
• 152020-32-1 Boc-Arg(Tos)-Gly-Asp(OcHex)-Val-OBzl 

Relevant articles and documents

Dual-acting agents that possess free radical scavenging and antithrombotic activities: Design, synthesis, and evaluation of phenolic tetrahydro-β-carboline RGD peptide conjugates

A new approach to construct a single dual-acting agent is described. Compounds 6a-c are potent free radical scavengers as demonstrated by the EC50 values in PC12 cell survival assay in term of NO, H2O2, and {radical dot}OH scavenging activity. The Ach-induced vaso-relaxation assay further confirms the potent NO scavenging activity of compounds 6a-c. In addition, 6a-c are efficacious in a rat arterial thrombosis, and are active in ADP- or PAF-induced in vitro platelet aggregation assay, suggesting that compounds 6a-c also possess anti-thrombotic activities. Since both free radical and thrombogenesis are important risk factors in myocardial ischemic/reperfusion injuries, these dual-acting agents having both free radical scavenging and antithrombolic activities may potentially be beneficial toward their treatment.

Studies on Hybrid Peptides of Fragments from Fibrinogen

In the present paper the hybrid peptides of P6A and RGD, namely ARPAKRGDS 17, ARPAKRGDV19, ARPAKRGDF 21, QRPAKRGDS 18, QRPAKRGDV 20 and QRPAKRGDF 22, were synthesized via the solution method, segment condensation and TFA/TFMS A-catalyzed deprotection (in